Chronic Graft-versus-Host Disease: How Can We Release Prometheus?  by Teshima, Takanori et al.
Biology of Blood and Marrow Transplantation 14:142-150 (2008)
Q 2008 American Society for Blood and Marrow Transplantation
1083-8791/08/1401-0001$32.00/0
doi:10.1016/j.bbmt.2007.10.023Chronic Graft-versus-Host Disease:
How Can We Release Prometheus?
Takanori Teshima,1 Thomas A. Wynn,2 Robert J. Soiffer,3 Ken-Ichi Matsuoka,3 Paul J. Martin4
1Center for Cellular and Molecular Medicine, Kyushu University Hospital, Fukuoka, Japan; 2 Immunopathogenesis
Section, Laboratory of Parasitic Diseases, National Institute of Allergy and Infectious Diseases, National Institutes
of Health, DHHS, Bethesda, Maryland; 3Hematologic Malignancies, Dana-Farber Cancer Institute, Boston,
Massachusetts; and 4Fred Hutchinson Cancer Research Center, Seattle, Washington
Correspondence and reprint request: Paul J. Martin, MD, Fred Hutchinson Cancer Research Center, P.O. Box 19024,
1100 Fairview Avenue N., D2-100, Seattle, WA 98109-1024 (e-mail: pmartin@fhcrc.org).INTRODUCTION
According to Greek mythology, Prometheus is
a Titan who stole fire fromZeus and gave it to humans.
As punishment, Zeus ordered Prometheus to be
chained on top of a mountain, where an eagle came
every day to eat his liver. Each day, his liver grew
back, only to be eaten again by the eagle. The Greeks
recognized Prometheus as an intelligent and cunning
character who acted courageously for the benefit of
humanity. As physicians and scientists engaged in
hematopoietic cell transplantation (HCT), we are the
intellectual heirs of our Promethean predecessors
who established this life-saving treatment through
great creativity, courage, and originality, but we are
also heirs of the punishment that follows in the form
of our struggles with the chronic graft-versus-host
disease (cGVHD) that afflicts many of our patients.
For the past 3 decades, we have used empiric treatment
with immunosuppressive agents tomanage the disease,
but we all recognize that progress since the mid to late
1980s has been limited. To gain ground, we need a bet-
ter understanding of the pathophysiology leading to
cGVHD and the regulation of the cells that cause
this disease. The beginning of such understanding
can be gained through studies of animal models and
biologic processes that mimic various characteristics142of cGVHD and through studies of the regulatory pro-
cesses that might serve to control the disease.
Chronic GVHD is a pleiomorphic syndrome with
onset generally occurring between 3 and 24 months
after allogeneic HCT [1]. The highly variable clinical
manifestations of cGVHD frequently involve the skin,
liver, eyes, mouth, upper respiratory tract, esophagus,
and less frequently involve serosal surfaces, lower gas-
trointestinal tract, female genitalia, and fascia [2]. The
biologic mechanisms leading to cGVHD are not as
well understood, as those leading to acute GVHD
(aGVHD). Although aGVHD has been recognized
as a risk factor for cGVHD, not all cases of aGVHD
evolve into cGVHD, and cGVHD can develop in
the absence of any prior overt aGVHD. In the skin,
the initial phase of cGVHD is characterized by an
intense mononuclear inflammatory infiltrate with
destructive changes at the dermal-epidermal junction,
accompanied by irregular acanthosis, hyperkeratosis,
or atrophy, progressing to dermal fibrosis and sclerosis
[3]. Other hallmarks include destruction of tubuloal-
veolar glands and ducts in the skin, salivary, and lacri-
mal glands and respiratory epithelium, and destruction
of bile ducts in the liver. These distinctive characteris-
tics make it clear that aGVHD and cGVHD have
different pathogenic mechanisms.Immunobiology of cGVHD: Insights from Animal
ModelsTakanori Teshima
Chronic GVHD is a multiorgan disorder with
features of immunodeficiency and autoimmunity.
The bewildering diversity of clinical manifestationsand lack of relevant animal models have made it diffi-
cult to characterize the pathophysiology of cGVHD.
The frequent emergence of cGVHD from aGVHD
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association could be explained if alloreactive donor T
cells are responsible for both aGVHD and cGVHD,
or if aGVHD or its treatment leads to the emergence
of T cells that cause cGVHD. aGVHD, however, is
not an absolute prerequisite for cGVHD, suggesting
that cGVHD is not simply a protracted form or end
result of aGVHD.
In humans, immunosuppressive treatment for
aGVHD permits a healing process, which may be fol-
lowed by atrophy and fibrosis not only in the skin,
liver, and gastrointestinal tract, but also in other
organs that can be affected by cGVHD. For example,
pathologic production of transforming growth factor-
b by donor-derived mononuclear cells might account
for fibrosis in organs affected by either cGVHD or
scleroderma [4]. These hypotheses remain difficult to
test directly, because few relevant animal models reca-
pitulate the pathologic continuity between aGVHD
and cGVHD. In most animal models, infused donor
T cells distinctively induce either aGVHDor cGVHD
in a manner that depends on the donor and recipient
strains. Thus, the temporal time course of cGVHD
in animal models does not mirror that in human
cGVHD. Nonetheless, results from animal studies
provide some important suggestions regarding the
pathogenic mechanisms that lead to cGVHD.
Given the close similarities between cGVHD and
autoimmune diseases, a long-standing hypothesis has
been that cGVHD results from pathogenic effects me-
diated by ‘‘autoimmune’’ T cells that recognize donor
antigens or shared antigens of the donor and recipient
rather than alloantigens of the recipient. This hypoth-
esis might explain why strategies that have successfully
prevented aGVHD do not consistently decrease the
risk of cGVHD. The autoimmune-type manifesta-
tions of cGVHD can present with multisystem fibro-
sis, most often involving the skin, salivary glands, and
lacrimal glands or with epitope-specific manifestations
such as thyroiditis, thrombocytopenia, and myasthenia
gravis [5]. Epitope-specific autoimmune diseases can
also occur after autologous HCT, although the patho-
genic mechanisms in autologous recipients may differ
from those in allogeneic recipients.
Several clinical observations suggest that such au-
toreactive T cells could be expanded or generated after
allogeneic HSCT. PR1 andWilms tumor 1 (WT1) are
peptides derived from nonpolymorphic self-antigens.
Frequencies of PR1- or WT1-specific CD81 T cells
arehigher afterHCTthanbeforeHCTor indonors [6].
Development of autoantibodies has long been rec-
ognized in cGVHD, although the clinical significance
of many autoantibodies remains unknown. How does
alloimmunity evolve into autoimmunity? First, an
autoreactive repertoire very likely exists in healthy
individuals, and homeostatic expansion after HCT-
induced lymphopenia with a failure of peripheralregulatory mechanisms could trigger a loss of self-tol-
erance. Second, tissue damage induced by alloreactive
T cells during aGVHDmay expose cryptic antigens to
the immune system or alter self-antigens in ways that
activate and expand autoreactive T cells. Tissue dam-
age also causes release of ‘‘danger signals’’ that further
facilitate this process. For example, results of a recent
study showed that T cells from mice with aGVHD
caused colitis after transfer into secondary immunode-
ficient mice of donor MHC type [7]. Absence of regu-
latory T cell control of Th1 and Th17 cells was
associated with this autoimmune-mediated pathology
in cGVHD [8]. Third, thymic damage by aGVHDdis-
rupts mechanisms of negative selection that eliminate
autoreactive T cells developing in the thymus [9].
aGVHD attacks epithelial cells, dendritic cells
(DCs), and Hassall’s corpuscles in the thymus. Au-
toreactiveTcells that escapenegative selection in a thy-
mus damaged by aGVHD then emerge into the blood
and secondary lymphoid organs [10-12]. When Has-
sall’s corpuscles are damaged, DCs in the thymus can-
not induce the development of functional regulatory T
cells, and the absence of regulatoryTcells allows autor-
eactive T cells in the periphery to cause the tissue dam-
age recognized as cGVHD. Immunosuppressive
agents such as calcineurin inhibitors also impair central
and peripheral mechanisms of tolerance [13].
T cell reconstitution after allogeneic HCT can be
mediated both by peripheral expansion of donor-
derived mature T cells infused with the graft and
generation of T cells from donor hematopoietic stem
cells (HSCs) that mature in the recipient thymus.
Recent evidence clearly demonstrates that thymopoiesis
continues even in adult HCT recipients. Experimental
studies in animal models have convincingly shown
that the infused donor T cells activated by recipient an-
tigen-presenting cells (APCs) mediate aGVHD. The
infusion of mature donor CD41 T cells can also cause
cGVHD [4,14]. On the other hand, donor T cells that
develop from engrafted HSCs can also cause cGVHD
[11,12]. Because recipient APCs are eventually elimi-
nated by the conditioning regimen and by donor T
cells, donor APCs may become increasingly important
in the propagation of GVHD across time after HCT.
Cutaneous cGVHD can be mediated by donor T cell
recognition of recipient alloantigens presented by do-
nor APCs [15]. Donor T cells isolated from mice with
aGVHD can transfer the disease into secondary recipi-
ents that had first been repopulated with donor APCs
[7,11]. The role of donor APCs suggest that CD41 T
cells may be more important than CD81 T cells in
the pathogenesis of cGVHD [11,12,14,16]. CD41
helper T cells are the key regulators of all immune re-
sponses, andmay be implicated inmany of the immuno-
biologic mechanisms that lead to cGVHD.
Several studies have addressed a role of B cells and
humoral immunity in human cGVHD [17-19]. In
144 T. Teshima et al.cGVHD, the B cell compartment paradoxically shows
simultaneous B-lymphocytopenia and B cell hyperre-
activity manifested by production of autoantibodies.
Although autoantibodies might merely reflect abnor-
mal reconstitution of T and B cells, a more direct
role of B cells has been suggested by experiments
showing that depletion of donor B cells can protect
mice from cGVHD [14]. Biomarker studies have
shown enhanced CD86 expression after TLR9 stimu-
lation of B cells from patients with cGVHD, compared
to those from controls [20]. Alloantibodies specific for
recipient minor histocompatibility antigens are also
detected in patients with cGVHD usually 4-6 months
after transplantation [17,18]. Patients with antibodies
to recipient minor antigens also have T cells specific
for the same antigens [19]. Beneficial effects of B cell
depletion by rituximab in some patients with refrac-
tory cGVHD further emphasize the potential patho-
genic role of B cells in the development of cGVHD
[21-23]. Agonistic antibodies against platelet-derived
growth factor receptor (PDGFR) were detected in se-
rum from each of 22 patients with clinical extensive
cGVHD but not in serum from any of 17 patients
without cGVHD [24]. These antibodies induce tyro-
sine phosphorylation of PDGFR, accumulation of
reactive oxygen species (ROS) and stimulation of
type 1 collagen gene expression by fibroblasts, through
a Ras and ERK1/2-dependent signaling pathway [25].
These results suggest novel approaches for treatment
of cGVHD, because ligand-induced phosphorylation
of the PDGFR is susceptible to inhibition by certain
tyrosine-kinase inhibitors, including imatinib.
Multiple cellular mechanisms that are both similar
and distinct from aGVHD are likely to be involved in
cGVHD. These include dysregulation of postthymicT cells and thymic-dependent T cells, donor and
recipient APCs, alloimmunity and autoimmunity, cel-
lular and humoral immunity, thus explaining complex
and protean clinical manifestations of cGVHD. Addi-
tionally, differences in target antigen distribution [16]
and polymorphisms in the regulatory regions of genes
that determine the nature of immune responses might
also explain the diversity of clinical presentation
among patients with cGVHD. Development of novel
strategies that enhance, rather than impair, the devel-
opment and maintenance of central and peripheral
tolerance mechanisms may be required to prevent
and treat cGVHD [12,26].
The results summarized above raise more ques-
tions than answers, and leave the impression that no an-
imalmodel fully replicates all of the features of cGVHD
in humans, and more importantly, that no single bio-
logic mechanism is likely to account for the diverse fea-
tures of cGVHD in humans. The disease is clearly
initiated by donor T cells that recognize recipient allo-
antigens, because the incidence of cGVHD can be de-
creased by exhaustive depletion of T cell from the
graft. On the other hand, evidence from animal models
has clearly demonstrated that ‘‘autoreactive’’ T cells and
B cells can contribute to pathogenesis of the disease
through mechanisms that do not necessarily depend
on prior aGVHDor thymic dysfunction. It seems likely
that binding of agonistic antibodies to cell surface mol-
ecules other than PDGFR might account for certain
manifestations of cGVHD. If so, then a range of small
molecule inhibitors of intracellular signal transduction
could 1 day be used to treat the disease. More impor-
tantly, elucidation of the mechanisms responsible for
generating pathogenic autoantibodies could provide
a basis for development ofmethods to prevent cGVHD.Pathophysiology of Fibrosis
Thomas A. WynnTissue fibrosis or scarring is a leading cause of mor-
bidity and mortality worldwide. Almost 45% of all
deaths in the Western world are attributed to some
type of chronic fibrotic disease. Fibrosis affects nearly
all tissues and organ systems. Diseases in which fibrosis
is a major cause of morbidity and mortality include the
interstitial lung diseases, liver cirrhosis, kidney disease,
heart disease, systemic sclerosis, as well as cGVHD,
among others. Fibrotic tissue remodeling can also influ-
ence cancermetastasis and accelerate chronic graft rejec-
tion in transplant recipients. Current treatments for
fibrotic disorders that target the inflammatory cascade
have been largely unsuccessful, primarily because the
mechanisms that are involved in fibrogenesis are believed
to be distinct from those involved in inflammation [27].Previous studies have shown that the Th2 cyto-
kines IL-4, IL-5, IL-13, and IL-21 each have distinct
roles in the regulation of tissue remodeling and fibrosis
[28,29]. IL-4 is found at increased levels in the bron-
choalveolar lavage fluids of patients with idiopathic pul-
monary fibrosis, in the pulmonary interstitium of
individuals with cryptogenic fibrosing alveolitis, and
in bloodmononuclear cells of those suffering from peri-
portal fibrosis. Development of postirradiation fibrosis
is also associatedwith increased levels of IL-4. Although
the extent to which IL-4 participates in the progression
of fibrosis varies in each disease, it has long been consid-
ered a potent pro-fibrotic mediator. In fact, some stud-
ies have suggested that IL-4 is nearly twice as effective
as TGF-b, another potent pro-fibrotic cytokine.
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mechanisms that lead to fibrosis has come from studies
of schistosomiasis in mice. The pathology resulting
from infection with Schistosoma mansoni in mice is pre-
dominantly caused by the host reaction to parasite eggs
that are laid in the portal venous system and subse-
quently trapped in the liver and intestine. Egg-induced
liver fibrosis can lead to portal hypertension, which
causes much of the morbidity and mortality associated
with the disease. One of the first in vivo reports to in-
vestigate the contribution of IL-4 in the pathogenesis
of fibrosis was a study of schistosomiasis in mice, in
which neutralizing antibodies to IL-4 were shown to
significantly reduce the development of hepatic fibro-
sis. Inhibitors of IL-4 have also been shown to reduce
dermal fibrosis in a chronic skin graft rejection model
and in mouse models of scleroderma.
IL-13 shares many functional activities with IL-4
because both cytokines exploit the same IL-4Ra/
Stat6-signaling pathway. However, with the develop-
ment of IL-13 transgenic and knockout mice, as well
as IL-13 antagonists, unique and nonredundant roles
for IL-13 and IL-4 have been revealed in numerous
models [30,31]. When IL-4 and IL-13 were inhibited
independently, IL-13 was identified as the dominant
effector cytokine of fibrosis in several experimental
models of fibrosis. In schistosomiasis, although the
egg-induced inflammatory response is unaffected by
IL-13 blockade, collagen deposition decreases by
more than 85% in chronically infected animals, despite
continued and undiminished production of IL-4.
Related studies have also shown a dominant role for
IL-13 in the pathogenesis of pulmonary fibrosis. In
contrast, interferon-g, IL-12, IL-10, and the IL-13
decoy receptor (IL-13Ra-2) all antagonize the pro-
fibrotic effects of IL-13.
IL-5 and eosinophils have also been shown to
regulate tissue fibrogenesis. The differentiation, activa-
tion, and recruitment of eosinophils are highly
dependent on IL-5, and eosinophils are an important
source of fibrogenic cytokines, including TGF-b1 and
IL-13. IL-5 and tissue eosinophils have been observed
in a variety of diseases including skin allograft rejection
and pulmonary fibrosis. Studies with neutralizing anti-
IL-5 antibodies and IL-5-deficient mice, however,have often yielded conflicting results regarding the
role of IL-5 and eosinophils in the development of fi-
brosis. Early experiments with neutralizing anti-IL-5
monoclonal antibodies (mAb) showed no reduction in
liver fibrosis following S. mansoni infection, even
though tissue eosinophil responses were markedly re-
duced. Although negative findings were also reported
with some of the skin and lung fibrosis models, other
studies observed significant reductions in fibrosis and
tissue remodeling when IL-5 activity was neutralized.
In IL-5-deficient mice, tissue eosinophilia is abolished
and the ability of CD41 Th2 cells to produce the pro-
fibrotic cytokine IL-13 is impaired. Eosinophils were
also found to be an important source of IL-13 in the
schistosomiasis-induced model of liver fibrosis [32].
IL-5 and eosinophils can also regulate the TGF-b re-
sponse in the lungs of mice. Thus, 1 of the key roles
of IL-5 and eosinophils may be to facilitate production
of important pro-fibrotic cytokines, including IL-13
and TGF-b, which function as the key mediators of
fibrosis.
Recent studies have shown that IL-21/IL-21R
signaling promotes fibrosis by facilitating the develop-
ment of aCD41Th2cytokine response, similar to the ef-
fectsof IL-5 [33]. IL-21R-signalingwas alsonecessary for
Th2-cell survival and for migration Th2 cells to periph-
eral tissues. In addition to supporting the development
ofTh2 responses, IL-21 increased IL-4 and IL-13 recep-
tor expression on macrophages, which enhances the de-
velopment of alternatively activated macrophages that
are believed to be important regulators of fibrosis.
Although not immediately obvious, experimental
schistosomiasis can be viewed as sharing certain immu-
nobiologic features with cGVHD. Both diseases are
mediated primarily byCD4 cells, and the characteristic
fibrosis that can appear in both diseases involves a type
2 polarized immune response. In schistosomiasis, im-
mune responses emerge from persistent stimulation
by egg-associated antigens that cannot be eliminated,
whereas immune responses in GVHD evolve, in part,
from persistent stimulation by recipient alloantigens
that likewise cannot be eliminated. Finally, both
diseases are ameliorated through IL-10-dependent
mechanisms that involve naturally occurring and in-
duced T regulatory mechanisms [34].T Regulatory Cells for Treatment of cGVHD:
Hercules to the Rescue?Robert J. Soiffer and Ken-Ichi Matsuoka
Chronic GVHD is the most significant long-term
problem facing patients who are cured of their malig-
nancy after allogeneic HCT. The incidence of
cGVHD appears to have increased over the past sev-eral years, in part because of grafting with mobilized
blood cells, particularly in the setting of reduced
intensity transplantation. Extensive cGVHD pro-
duces substantial morbidity and late mortality.
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are often ineffective. A variety of other treatment op-
tions have been investigated with limited success.
The increased frequency of cGVHD after HCT with
blood cells compared to bone marrow might result
from the greater number of mature T cells infused
with graft [35]. Depletion of donor T cells by ex vivo
manipulation or through administration of anti-T
cell antibodies has been associated with a reduced
risk of cGVHD [36], but global T cell depletion has
generally not improved overall transplant outcomes
because of higher rates of graft rejection, disease re-
lapse, and viral infections.
As the complexity of the immune response has
been elucidated, attention has turned to the role of spe-
cific T cell subsets in modulating graft-versus-host re-
actions. Indeed, in the early 1980s, researchers from
Seattle identified allo-suppressive lymphocytes of
donor origin in long-term survivors without cGVHD
[37], suggesting that although some donor lympho-
cytes might induce GVHD, others might suppress
the reaction. The recognition that particular T cells
subsets exert a regulatory function that can suppress
immune reactions (so-called regulatory T cells
[Treg]) has stimulated interest in manipulating these
cells to help control both aGVHD and cGVHD.
Treg were first described as a subpopulation of
CD4 cells with immune suppressive properties that
constitutively express the interleukin-2 (IL-2) recep-
tor alpha chain (CD25). They represent approxi-
mately 5% of circulating CD41 T cells [38]. In
murine studies, CD41 T cells depleted (TCD) of
CD251 cells could induce autoimmune phenomena,
whereas transfer of CD41CD25High T cells could pro-
tect recipients from autoimmune-mediated diabetes
[39,40]. Because activated CD4 cells may also express
CD25, precise immunophenotypic characterization
that specifically identifies Treg has been challenging.
Foxp3, a forkhead transcription factor, is critical to
the suppressive function of Treg and can help discrim-
inate them from activated CD4 cells [41,42]. Also
helpful has been the observation that the alpha chain
of the IL-7 receptor (CD127), typically present on ac-
tivated CD41 cells, is not expressed on Treg. Sorted
CD41CD251CD1272 T cells exhibit suppressive
activity in vitro [43,44]. Expression of CD39, CD73,
and folate receptor 4 may help further refine Treg
characterization [45,46]. In human studies, patients
with certain autoimmune diseases, including systemic
lupus erythematosus (SLE), rheumatoid arthritis, and
multiple sclerosis exhibit deficiencies in Treg number
and function [47-49]. The congenital absence of Treg
in IPEX syndrome results in lymphoproliferation and
fatal uncontrolled autoimmunity [50,51].
The relationship between Treg and autoimmune
phenomena in murine models and in human disease
prompted interest in their potential role in GVHD.In murine studies, depletion of CD41CD251 T cells
from the donor graft increased mortality related to
GVHD [52]. In other experiments, adoptive transfer
of donor Treg along with conventional T cells at the
time of bone marrow transplantation could prevent
or mitigate GVHD [53-55]. Although Treg could
prevent GVHD, it has not been clear that transferred
Treg can effectively halt GVHD after it has begun
[56].
The mechanisms by which Treg suppress graft-
versus-host reactions remains uncertain, but there is
evidence that migration of Treg to secondary
lymphoid organs and colocalization with effector T
cells at those sites are critical steps [57-59]. Several
studies suggest that suppression is mediated by cyto-
kines such as TGF-b and IL-10 or by activation of
plasmacytoid dendritic cells through indoleamine
2,3-dioxygenase (IDO) [60,61]. Treg may also exert
inhibitory influence directly in target tissues [59]. A
reduction in the number of mucosal Foxp31 regula-
tory T cells has been documented in patients with
aGVHD and cGVHD compared to normal controls
or patients without GVHD [62]. Treg rendered inca-
pable of migrating to target tissues have a diminished
capacity to eliminate or modulate GVHD [63].
Studies in humans have attempted to correlate
Treg number either in the graft before infusion or in
the blood of patients with aGVHD or cGVHD after
transplantation. Lower numbers of Treg in the graft
have been associated with the development of aGVHD
after transplant [64,65]. A similar relationship has been
observed after administration of donor lymphocyte in-
fusions (DLI) [66]. No clear association between Treg
content in the graft and cGVHD has been reported,
although both murine and human data have suggested
that recipient Treg surviving the conditioning regimen
could influence the development of cGVHD [67,68].
Several teams have tested blood samples from patients
at various stages after transplantation and found that
the number of CD41CD251Foxp31 T cells was
inversely related to the incidence of either aGVHD
or cGVHD [62,64,67,69,70].
Not all studies have confirmed this correlation,
and in some studies, Treg were associated with
a greater incidence of cGVHD [71-74]. Data regard-
ing Treg number and its influence on recurrent malig-
nancy are not consistent among different studies
[65,75]. Ambiguity in the immunophenotypic identifi-
cation of Treg makes it difficult to evaluate many of
these reports. Treg might not all exhibit uniform
suppressive activity, and there is evidence that alloan-
tigen-driven Treg may differ from Treg generated
under homeostatic conditions as in states of lympho-
penia-induced proliferation (LIP) [76,77]. Also, it
remains unclear whether the blood compartment is
representative of Treg content and activity in second-
ary lymphoid organs and target tissues. Treg number
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enous or exogenous factors such as cytokines or
immune suppressive medications. Exposure to TNF
and perhaps other inflammatory cytokines can reduce
Foxp3 expression and impair suppressive activity
[78]. In addition, immunosuppressive medications
such as calcineurin inhibitors and sirolimus might dif-
ferentially affect Treg function [79,80]. Last, recovery
of a broad Treg Vb repertoire diversity might be more
important than the number of Treg in regulating the
development of cGVHD [81].
Although the biologic control of Treg and their
direct impact on GVHD remain incompletely defined,
significant enthusiasm has emerged for manipulating
Treg either ex vivo or in vivo for clinical benefit.
Murine studies have demonstrated that Treg can be
expanded ex vivo in the presence of IL-2 after activa-
tion by anti-CD3 and anti CD28monoclonal antibody
immobilized on microbeads [56,57,82,83]. These
Treg retain immune suppressive properties, and
when added the to the graft can reduce the risk of
GVHD in mice. Treg expanded after exposure to
APCs and IL-2 may be even more effective. These
recipient-specific Treg can suppress GVHD more
efficiently than freshly isolated Treg or polyclonal
Treg in murine models [84,85]. Treg expanded in
the presence of APCs derived specifically from gut
and skin might preferentially home in to target tissues
after infusion and could theoretically be utilized to
treat end organ manifestations of cGVHD [86,87].
Despite these promising observations in murine
studies, ex vivo expansion of cells for human transplan-
tation is cumbersome and does not yet appear to yield
reliably reproducible products for clinical use. Initial
studies will be needed to determine how long
expanded Treg survive and function in vivo to define
the most appropriate schedule of infusions in treat-
ment protocols for established cGVHD.
An alternative approach for patients with estab-
lished GVHD could be directed toward in vivo expan-
sion of Treg. Calcineurin inhibitors downregulate
Treg, whereas agents like rapamycin and mycopheno-
late mofetil preserve and promote Treg activity
[13,88-91]. Uncontrolled studies have indicated the
activity of these 2 agents in cGVHD [92-94], whereas
calcineurin inhibitors have not demonstrated any
substantial value when added to corticosteroids for
treatment of cGVHD [95]. Treatment with extracor-
poreal photopheresis has produced improvement in
some patients with cGVHD [96]. Although the mech-
anisms of action of extracorporeal photopheresis in
cGVHD remain undefined, data are emerging to
suggest that extracorporeal photopheresis could act
by generating Treg in vivo [97,98].
Another strategy is predicated upon the demon-
stration that IL-2 is essential to the generation and
expansion of Treg in vivo [76,99]. Laboratory studiesfrom clinical trials of low dose recombinant IL-2 in
patients with HIV infection or cancer have shown
that Treg numbers are increased in these patients
[100,101]. After HCT, prolonged low-dose IL-2
administration preferentially expands Tregs compared
to conventional T cells and does not induce GVHD
[102]. A study that evaluated the use of CD8-depleted
DLI followed by 8 weeks of low-dose IL-2 designed to
increase GVL activity resulted in a large expansion of
CD41CD251Foxp31 Treg with potent immune sup-
pressive properties (Zorn et al, manuscript in prepara-
tion). A clinical trial evaluating the safety and efficacy
of low-dose IL-2 in patients with established cGVHD
is now underway.
CONCLUSIONS AND FUTURE DIRECTIONS
Studies with animal models have suggested that
failure of the thymus to delete ‘‘autoimmune’’ T cells
is at least 1 potential mechanism that might contribute
to the pathogenesis of cGVHD. Results of a very re-
cent study with mice have suggested that prophylactic
administration of keratinocyte growth factor could be
used to improve thymic function after allogeneic
HCT, thereby preventing cGVHD [12]. Further stud-
ies are needed to translate the emerging understanding
of the molecular mechanisms of fibrosis into successful
intervention strategies for treatment of chronic
fibrotic disorders such as cGVHD.Our understanding
of Treg biology and its influence on GVHD after
transplantation remains in its infancy. The precise
immunophenotypic characterization of Treg is being
refined, and efforts to define the role of Treg in the de-
velopment and resolution of aGVHD and cGVHD
will likely culminate in clinical trials to manipulate
Treg as a potential way of improving outcomes after
allogeneic HCT.
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